Medicare cracks down on PBM middlemen: forced transparency, affiliate disclosure, and pharmacy acces

What it does

This bill requires Medicare prescription drug plans to accept any pharmacy meeting standard contract terms ("any willing provider"), establishes federal standards for what constitutes reasonable contract terms by 2028, and imposes strict transparency and accountability rules on pharmacy benefit managers (PBMs). PBMs must disclose detailed drug pricing, rebate arrangements, and affiliate relationships; cannot profit from sources other than flat-fee services; and face enforcement through civil penalties and disgorgement of improper payments. Independent pharmacies and small chains benefit from reduced network exclusion; Medicare beneficiaries gain visibility into drug costs and PBM conflicts of interest.

Why we flagged it

The bill's core mechanism is regulatory constraint on PBM profit-taking and information asymmetry, not a subsidy or carve-out. It mandates disclosure, restricts self-dealing, and creates enforcement pathways—classic accountability legislation. The 'Patients Before Middlemen' title accurately reflects the functional intent.

What the text implies

• PBMs may respond by consolidating further or shifting costs to plan sponsors via higher service fees (which are permitted if flat-rate and fair-market-value). The bill does not cap fees, only requires transparency and bona-fide-service justification.
• The 'essential retail pharmacy' definition and reporting regime may create a two-tier system: protected pharmacies in underserved areas receive preferential treatment, while urban/suburban chains face network exclusion pressure. This could fragment pharmacy networks.
• Affiliate disclosure requirements expose PBM-owned pharmacies' preferential dispensing patterns. If PBMs cannot hide affiliate profit-taking, they may divest pharmacy assets or restructure ownership to obscure relationships—regulatory arbitrage.
• The bill requires Secretary to establish 'reasonable and relevant' contract standards by April 2027, but does not define the standard itself. Implementation risk is high; weak standards would hollow the bill's intent.
• Confidentiality provisions (Section 1860D–12(6)) restrict public disclosure of contract prices and rebates even after reporting. Beneficiaries and researchers may not see the data the bill mandates be collected, limiting transparency to government oversight only.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts PBM market power and self-dealing (a major source of hidden drug cost inflation), mandates transparency that exposes conflicts of interest, and protects pharmacy access—especially in underserved areas. Beneficiaries gain leverage to challenge unfair contract terms and visibility into why their drugs cost what they do. The enforcement mechanism (civil penalties, disgorgement, audit rights) is real and backed by Secretary authority.

Who stands to gain

• independent pharmacies and small pharmacy chains (reduced network exclusion, access to contracts)
• Medicare beneficiaries (lower out-of-pocket costs if PBM rebates are passed through; visibility into
• generic drug manufacturers (formulary bias against generics will be exposed and challenged)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Pharmacy Benefit Managers (PBMs), PDP sponsors (prescription drug plan sponsors), MA organizations (Medicare Advantage organizations), MA-PD plans (Medicare Advantage Prescription Drug plans), Independent pharmacies, Retail pharmacy chains, Drug manufacturers, Office of Inspector General (HHS), Secretary of Health and Human Services

Where it stands

7 cosponsors: 4 Democrats, 3 Republicans.

• Mar 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 6, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 lobbying clients named this bill on 18 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $18,476,656 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

Marsha Blackburn, the sponsor, reported $133,620 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• Pharmaceutical Care Management Association — $6,472,656 on 2 filings
• Elevance Health, Inc. — $4,010,000 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Food Marketplace Inc — $1,384,000 on 2 filings
• Cambia Health Solutions — $1,330,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.